Source-grounded facts extracted from Insight Molecular Diagnostics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).
“On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).”
Insight Molecular Diagnostics Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC (effective 2026-02-10).
“The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.”
Insight Molecular Diagnostics Inc. entered into Purchase Agreements with certain institutional investors valued at approximately $24.5 million (effective 2026-02-10).
“On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.”
Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).
“Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.”
Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).
“In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.”
James Liu changed role as Vice President Accounting, Controller, Treasurer and Principal Accounting Officer at Insight Molecular Diagnostics Inc..
“On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.”
Andrea James was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..
“On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.”
Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.
“Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.”
Insight Molecular Diagnostics Inc. reported year ended December 31, 2023 results: revenue $1.5 million.
“commercial and regulatory milestones.” 2023 Fourth Quarter and Full-Year Financial Results Net revenue for the three months and year ended December 31, 2023, was $314,000 and $1.5 million, respectively, an increase of 15% compared to the fourth quarter 2022 and 57% compared to the full year 2022, due to increased revenue from Pharma Services. Cost of revenues for”
Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).
“On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.”
Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).
“On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.